Autopsy report · NCT00622089

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

“Program terminated”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 11 months before it stopped.
• 150 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

DiObex

Sponsor type

Industry

Conditions

Type 2 Diabetes

Interventions

DIO-902; DIO-902; DIO-902

Participants

150 (planned, not actual)

Sites

24

Countries

Australia, New Zealand, United States

Trials that died the same way

• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
  “Development program terminated” (82% match in meaning)
• GALLANT 22 Tesaglitazar vs. Placebo
  “The development program has been terminated” (70% match in meaning)
• Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone
  “terminated by PI” (63% match in meaning)
• Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
  “Program terminated due to lack of meaningful efficacy signal.” (59% match in meaning)
• Physician's Comfort Level and Satisfaction Study With The e2TM Collector Compared to the Spatula/CytoBrush Technique
  “Terminated for lack of resources to complete.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.